1627. Tablet OR Suspension Of posacoanazole study(TORSO study)
Session: Poster Abstract Session: Mycology - There's a Fungus Among Us: Treatment
Friday, October 28, 2016
Room: Poster Hall
Posters
  • IDWeekTORSOposteruploadfinal.pdf (1.6 MB)
  • Background: The TORSO study was designed to understand if patients prefer one of the two available oral formulations of posaconazole. Oral tablet posaconazole is the preferred formulation to optimize plasma concentrations. However, patient preference in terms of convenience (ease of use) was unknown. The oral suspension shows variable absorption depending on food intake. The primary end point was overall patient preference. Secondary end points included awareness and adherence to food requirements. Methods: Centres routinely treating AML and MDS patients were approached. A questionnaire was completed by patients who had received both oral formulations as part of their normal care. In order to minimize recall bias, patients should have received both formulations for a minimum of 7 days (non-interventional, convenience sample) and within the last 42 days. Patients who switched from oral suspension to oral tablet posaconazole (or vice versa) and who met the inclusion criteria were identified by nurses. The analysis was descriptive, no statistical hypotheses were tested. Data collected were categorical and summarised using counts and percentages. Results: 21 adult patients completed questionnaires from 3 UK haematology centres of which, 17 patients (81%, 95% CI 60%-92%) expressed an overall preference for the tablet formulation. No patients indicated difficulties in swallowing solids or liquids. Knowledge of how to take the formulation was generally low with 1 patient (5%) aware that the suspension needs to be taken with a high fat meal. 17 patients (81%) preferred the taste of the tablet. Conclusion: Patients in this study were shown to prefer the tablet formulation over the suspension with taste being a major determinant of their preference. Furthermore, no patients usually took their suspension with a high fat meal. Patients receiving complex regimes for the management of AML and MDS are at high risk of invasive fungal infections due to periods of neutropenia, which can lead to poor patient outcomes and high healthcare expenditure. Patient preference and ability to adhere to food requirements are important considerations for clinicians to minimize the risk of breakthrough invasive fungal infections.
    Harpal Dhillon, PhD MRPharmS, Darren Cooper, BPharm MRPharmS, Helen Tate, Statistician, Jude Robinson, Medical Affairs Research Manager and Harpal Lamba, BSc MBA MFPM FRCP(UK), Medical Affairs, Merck Sharp & Dohme, Hoddesdon, United Kingdom

    Disclosures:

    H. Dhillon, Merck Sharp & Dohme: Employee , Salary

    D. Cooper, Merck Sharp & Dohme: Employee , Salary

    H. Tate, Merck Sharp & Dohme: Independent Contractor , Salary

    J. Robinson, Merck Sharp & Dohme: Employee , Salary

    H. Lamba, Merck Sharp & Dohme: Employee , Salary

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.